PEBP1 and metastatic neoplasm: The loss of RKIP expression in secondary, not primary, tumors is a concern because RKIP-targeted therapies would target secondary tumors, but if resistance to such therapies was conferred to secondary tumors, the treatment would be ineffective in inhibiting further invasion and mobility of metastatic tumors.